Lem Moye
Overview
Explore the profile of Lem Moye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostovaneh M, Ward C, Ambale-Venkatesh B, Chamera E, Kato Y, Bolli R, et al.
JACC Cardiovasc Imaging
. 2022 Jan;
15(5):952-954.
PMID: 35033497
No abstract available.
2.
Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J, et al.
Eur J Heart Fail
. 2021 Apr;
23(4):661-674.
PMID: 33811444
Aims: CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given...
3.
Bolli R, Perin E, Willerson J, Yang P, Traverse J, Henry T, et al.
JACC CardioOncol
. 2021 Jan;
2(4):581-595.
PMID: 33403362
Background: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach...
4.
Wang X, Chacon L, Derakhshandeh R, Rodriguez H, Han D, Kostyushev D, et al.
PLoS One
. 2020 Aug;
15(8):e0237401.
PMID: 32841277
Implantation of bone marrow-derived cells (BMCs) into mouse hearts post-myocardial infarction (MI) limits cardiac functional decline. However, clinical trials of post-MI BMC therapy have yielded conflicting results. While most laboratory...
5.
Bolli R, Hare J, Henry T, Lenneman C, March K, Miller K, et al.
Am Heart J
. 2018 Jun;
201:54-62.
PMID: 29910056
Objectives: SENECA (StEm cell iNjECtion in cAncer survivors) is a phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and feasibility of delivering allogeneic mesenchymal stromal cells (allo-MSCs) transendocardially...
6.
Bolli R, Hare J, March K, Pepine C, Willerson J, Perin E, et al.
Circ Res
. 2018 Apr;
122(12):1703-1715.
PMID: 29703749
Rationale: Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic...
7.
8.
Jokerst J, Cauwenberghs N, Kuznetsova T, Haddad F, Sweeney T, Hou J, et al.
Sci Rep
. 2018 Mar;
8(1):4257.
PMID: 29511207
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
9.
Traverse J, Henry T, Pepine C, Willerson J, Chugh A, Yang P, et al.
Circ Res
. 2017 Dec;
122(3):479-488.
PMID: 29208679
Rationale: The TIME trial (Timing in Myocardial Infarction Evaluation) was the first cell therapy trial sufficiently powered to determine if timing of cell delivery after ST-segment-elevation myocardial infarction affects recovery...
10.
Jokerst J, Cauwenberghs N, Kuznetsova T, Haddad F, Sweeney T, Hou J, et al.
Sci Rep
. 2017 Jul;
7(1):4419.
PMID: 28667255
Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77...